TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Interventions: TAS-102: 35mg/m2 given orally twice daily on days 1-5 and 15-19 in a 28-day cycle. Bevacizumab: 5mg/kg given intravenously in a 2-week cycle Primary outcome(s): progression free survival Study Design: Single arm Non-randomized
创建时间：
2018-12-15
